KSHV/HHV8-associated lymphomas.
This review looks at the current state of knowledge on primary effusion lymphoma (PEL) and other Kaposi sarcoma herpesvirus (KSHV)/human herpesvirus 8 (HHV8)-associated lymphomas. In 1995, KSHV DNA sequences were identified within a distinct subgroup of acquired immunodeficiency syndrome-related non-Hodgkin lymphomas localized in body cavities and presenting as pleural, peritoneal and pericardial lymphomatous effusions. Subsequently, the spectrum of KSHV/HHV8-associated lymphomas has been expanded by the identification of cases of extracavitary solid lymphomas without serous effusions. Despite the diversification in the clinical presentation of KSHV/HHV8-associated lymphomas, the majority of the cases reported demonstrated similar morphology, immunophenotype and KSHV/HHV8 viral status. KSHV/HHV8 infection is also in multicentric Castleman disease-associated plasmablastic lymphoma. The exact oncogenic mechanisms of KSHV/HHV8 are not clearly defined. The prognosis for KSHV/HHV8-associated lymphomas is poor. Novel approaches for therapy, outside traditional chemotherapy with CHOP (cyclophosphamide, doxorubicin, prednisone, vincristine), have been suggested. These include the addition of antiviral therapy as well as inhibition of specific cellular targets.
Carbone
Antonino
A
Department of Pathology, Istituto Nazionale Tumori, Milan, Italy. antonino.carbone@istitutotumori.mi.it
Gloghini
Annunziata
A
D006566:Herpesviridae Infections / Q000473:pathology / Q000628:therapy; D019288:Herpesvirus 8, Human; D006801:Humans; D008223:Lymphoma / Q000473:pathology / Q000628:therapy / Q000821:virology*; D016483:Lymphoma, AIDS-Related / Q000473:pathology / Q000628:therapy / Q000821:virology; D011379:Prognosis